Latest revenue
$879.4K
as of 2026-03-31
Latest net income
$-550.4K
as of 2026-03-31
Net margin
-62.6%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $987.2K
- Enterprise value
- $987.2K
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $0.00
- 52-wk low
- $0.00
- Beta
- —
- Shares out
- 617.0M
5-year trend
What this company does
Item 1. Business Historical background Target Group Inc. (“Target Group” or the “Company”) was incorporated in the State of Delaware on July 2, 2013, under its original name of River Run Acquisition Corporation. Effective May 13, 2014, the Company changed its name to Chess Supersite Corporation. On July 3, 2018, the Company filed an amendment in its Certificate of Incorporation to change its name to Target Group Inc. Effective July 1, 2025, the Company’s common stock is quoted on the Pink Limited Market operated by OTC Markets Group Inc, under the symbol “CBDY”. Cannabis Business-Canada The Company is engaged in the cultivation, processing and distribution of curated cannabis products for…
AI summary unavailable — showing raw filing excerpt
Generated from CBDY's filing dated 2026-03-31
Key risks
Item 1A Risk Factors. In addition to all other information set out in this Report, including our consolidated financial statements and the related notes included elsewhere in this Report, our business is subject to a number of risks that are uniquely applicable to the cannabis business generally and specifically in the cannabis business in Canada. Other risks and uncertainties that we do not presently consider material, or of which we are not presently aware, may become important factors that affect our future financial condition and results of operations. Risks Related to Our Cannabis Business and the Cannabis Industry in the United States As of the date of this report, the Company and its…
AI summary unavailable — showing raw filing excerpt
Generated from CBDY's filing dated 2026-03-31
Profitability
Gross margin
53.3%
5.7%Net margin
-35.0%
1538.8%Return on equity
16.9%
783.7%Return on assets
-22.0%
1138.7%Leverage
Debt / equity
-1.77×
18.4%Debt / assets
230.5%
24.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $879.4K | -37.2% | $-550.4K | -408.6% | -62.6% |
Q4 2025 2025-12-31 | $735.2K | -60.4% | $-552.3K | -758.0% | -75.1% |
Q3 2025 2025-09-30 | $499.6K | -7.7% | $-479.4K | -764.5% | -95.9% |
Q2 2025 2025-06-30 | $1.2M | -45.2% | $-219.8K | -146.4% | -17.6% |
Q1 2025 2025-03-31 | $1.4M | -27.1% | $-108.2K | +44.0% | -7.7% |
Q4 2024 2024-12-31 | $1.9M | — | $-64.4K | — | -3.5% |
Q3 2024 2024-09-30 | $541.1K | -48.3% | $-55.5K | +60.0% | -10.2% |
Q2 2024 2024-06-30 | $2.3M | +199.7% | $473.5K | +117.1% | 20.8% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Medicinal Chemicals & Botanical Products · SIC 2833
Your notes
Keep private notes on CBDY — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for CBDY in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns CBDY
No institutional holdings on file for CBDY yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once CBDY's latest filing finishes processing.